Apollo Education Group, Inc.
APOL
NASDAQ10.00
USD
+0.01
- -
Apollo Education Group, Inc.
APOL
(NASDAQ)
Recent
price
10.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Apollo Education Group, Inc. provides higher education programs primarily targeting working adults through both online and on-campus delivery. Its core offerings include undergraduate and graduate degree programs, certificate programs, and non-degree educational services. Key educational brands under Apollo include the University of Phoenix, which offers over 100 degree programs ranging from associate to doctoral levels with open enrollment policies. The company also serves the professional development and human capital management sectors via subsidiaries and its investment platform, Apollo Education Ventures, which supports innovation in education technologies and services. Founded in 1973 and headquartered in Phoenix, Arizona, Apollo Education Group operates primarily in the United States with a focus on adult learners. Recent major changes include its acquisition by an investor consortium involving Apollo Global Management and The Vistria Group, leading to privatization in 2024; the University of Phoenix has introduced new degree programs such as a Master of Science in Nursing. Furthermore, the group has been exploring strategic options including a possible IPO or sale of its University of Phoenix entity as of 2025. Apollo Education Group has also recently launched new technology platforms aimed at modernizing student data management to enhance educational outcomes and institutional efficiencies. These developments reflect a strategic shift towards innovation in educational delivery and expansion of professional and continuing education services within its core footprint.
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease